ECSP20042640A - Derivados de indol 1, 3, 4, 5-tetrahidro-2h-pirido [4,3-b] para el tratamiento, alivio o prevención de trastornos asociados con agregados de tau como la enfermedad de alzheimer - Google Patents

Derivados de indol 1, 3, 4, 5-tetrahidro-2h-pirido [4,3-b] para el tratamiento, alivio o prevención de trastornos asociados con agregados de tau como la enfermedad de alzheimer

Info

Publication number
ECSP20042640A
ECSP20042640A ECSENADI202042640A ECDI202042640A ECSP20042640A EC SP20042640 A ECSP20042640 A EC SP20042640A EC SENADI202042640 A ECSENADI202042640 A EC SENADI202042640A EC DI202042640 A ECDI202042640 A EC DI202042640A EC SP20042640 A ECSP20042640 A EC SP20042640A
Authority
EC
Ecuador
Prior art keywords
alzheimer
disease
prevention
treatment
tetrahidro
Prior art date
Application number
ECSENADI202042640A
Other languages
English (en)
Inventor
Sreenivasachary Nampally
Emanuele Gabellieri
Jérome Molette
Original Assignee
Ac Immune Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ac Immune Sa filed Critical Ac Immune Sa
Publication of ECSP20042640A publication Critical patent/ECSP20042640A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Testing Relating To Insulation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a compuestos novedosos que pueden emplearse en el tratamiento, alivio o prevención de un grupo de trastornos y anomalías asociados con los agregados de proteínas Tau (unidad asociada a tubulina) que incluyen, entre otros, los ovillos neurofibrilares (NFT), tal como la enfermedad de Alzheimer (AD).
ECSENADI202042640A 2018-01-05 2020-07-22 Derivados de indol 1, 3, 4, 5-tetrahidro-2h-pirido [4,3-b] para el tratamiento, alivio o prevención de trastornos asociados con agregados de tau como la enfermedad de alzheimer ECSP20042640A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18150422 2018-01-05
EP18175852 2018-06-04

Publications (1)

Publication Number Publication Date
ECSP20042640A true ECSP20042640A (es) 2020-09-30

Family

ID=65010781

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202042640A ECSP20042640A (es) 2018-01-05 2020-07-22 Derivados de indol 1, 3, 4, 5-tetrahidro-2h-pirido [4,3-b] para el tratamiento, alivio o prevención de trastornos asociados con agregados de tau como la enfermedad de alzheimer

Country Status (22)

Country Link
EP (1) EP3735411B1 (es)
JP (2) JP7225251B2 (es)
KR (1) KR102477105B1 (es)
CN (1) CN111757882B (es)
AU (2) AU2019205087B2 (es)
BR (1) BR112020012833A2 (es)
CA (1) CA3086759C (es)
CL (1) CL2020001796A1 (es)
CO (1) CO2020008287A2 (es)
CR (1) CR20200326A (es)
EC (1) ECSP20042640A (es)
ES (1) ES2989145T3 (es)
IL (1) IL275781B2 (es)
JO (1) JOP20200167A1 (es)
MA (1) MA51520A (es)
MX (1) MX2020007031A (es)
NZ (1) NZ765495A (es)
PE (1) PE20211090A1 (es)
PH (1) PH12020500573A1 (es)
SG (1) SG11202005607WA (es)
WO (1) WO2019134978A1 (es)
ZA (1) ZA202003769B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113453688A (zh) * 2019-03-01 2021-09-28 Ac免疫有限公司 用于治疗、减轻或预防与Tau聚集体相关的病症的新化合物
CN110845457B (zh) * 2019-10-22 2022-06-10 中国药科大学 松萝酸衍生物及其制法和在阿尔茨海默病药物中的应用
CN112791078B (zh) * 2019-11-13 2022-12-06 润佳（苏州）医药科技有限公司 同位素富集的3-氨基-1-丙磺酸及其衍生物的用途
CA3172102A1 (en) 2020-03-19 2021-09-23 Sonia Maria Poli Dose treatments of tauopathies
KR20230051168A (ko) * 2020-07-02 2023-04-17 레믹스 테라퓨틱스 인크. 2-(인다졸-5-일)-6-(피페리딘-4-일)-1,7-나프티리딘 유도체, 및 핵산 스플라이싱의 조절제로서의 및 증식성 질환의 치료를 위한 관련 화합물
CN117015536A (zh) * 2020-07-02 2023-11-07 雷密克斯医疗公司 作为核酸剪接和增殖性疾病治疗的调节剂的2-(吲唑-5-基)-6-(哌啶-4-基)-1,7-萘啶衍生物及相关化合物
AR123730A1 (es) * 2020-10-15 2023-01-04 Ac Immune Sa Compuestos novedosos
KR102231446B1 (ko) * 2021-01-21 2021-03-24 (주) 와이디생명과학 베타아밀로이드 및 타우 단백질 집적과 연관된 질환 치료용 약학적 조성물
WO2023025109A1 (zh) * 2021-08-23 2023-03-02 上海维申医药有限公司 一类Toll样受体抑制剂及其制备和应用
US20250092065A1 (en) * 2022-01-05 2025-03-20 Remix Therapeutics Inc. 2-(indazol-5-yl)-6-(piperidin-4-yl)-1,7-naphthyridine derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases
KR102856378B1 (ko) * 2022-09-30 2025-09-08 주식회사 젬백스앤카엘 4r 타우병증의 치료 또는 예방용 펩티드
EP4644396A1 (en) * 2022-12-28 2025-11-05 Visionpharma (Nantong) Co., Ltd Toll-like receptor inhibitor, and preparation therefor and application thereof
WO2025134068A1 (en) * 2023-12-22 2025-06-26 Ac Immune Sa Antibody drug conjugates targeting proteinopathies, and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ541282A (en) 2002-12-24 2009-02-28 Bellus Health International Ltd Therapeutic formulations for the treatment of beta-amyloid related diseases
AR049300A1 (es) * 2004-06-15 2006-07-12 Schering Corp Compuestos triciclicos antagonistas de mglur1 como agentes terapeuticos
JP2009527542A (ja) 2006-02-23 2009-07-30 ファイザー・プロダクツ・インク Ｐｄｅ１０阻害薬としての置換キナゾリン
MX2010008198A (es) * 2008-02-25 2010-08-23 Hoffmann La Roche Inhibidores de cinasa de pirrolopirazina.
US8853391B2 (en) 2008-12-18 2014-10-07 Merck Patent Gmbh Tricyclic azaindoles
WO2011084439A1 (en) * 2009-12-17 2011-07-14 Sanofi Tetrahydrocarboline derivatives as eg5 inhibitors
CA2794808C (en) 2010-04-16 2019-08-20 Ac Immune S.A. Compounds for the treatment of diseases associated with amyloid or amyloid-like proteins
WO2016090296A1 (en) * 2014-12-05 2016-06-09 Subramaniam Ananthan Heterocyclic compounds as biogenic amine transport modulators
EP3118202A1 (en) * 2015-07-15 2017-01-18 AC Immune S.A. Dihydropyridopyrrole derivatives as tau-pet-ligands
WO2017009454A1 (en) * 2015-07-15 2017-01-19 Ac Immune S.A. Novel imaging compounds

Also Published As

Publication number Publication date
NZ765495A (en) 2024-02-23
ZA202003769B (en) 2025-04-30
JP2022172130A (ja) 2022-11-15
WO2019134978A1 (en) 2019-07-11
EP3735411A1 (en) 2020-11-11
PH12020500573A1 (en) 2021-05-10
AU2019205087B2 (en) 2021-06-10
CA3086759C (en) 2025-06-17
JP2021510151A (ja) 2021-04-15
IL275781B1 (en) 2023-11-01
KR20200096570A (ko) 2020-08-12
AU2019205087A1 (en) 2020-07-02
AU2021203340B2 (en) 2022-11-24
CR20200326A (es) 2020-12-09
EP3735411B1 (en) 2024-07-10
JP7225251B2 (ja) 2023-02-20
AU2021203340A1 (en) 2021-06-24
CN111757882B (zh) 2023-08-22
MA51520A (fr) 2021-04-14
PE20211090A1 (es) 2021-06-14
BR112020012833A2 (pt) 2021-01-05
IL275781B2 (en) 2024-03-01
SG11202005607WA (en) 2020-07-29
CO2020008287A2 (es) 2020-10-30
MX2020007031A (es) 2020-12-03
JOP20200167A1 (ar) 2022-10-30
ES2989145T3 (es) 2024-11-25
IL275781A (en) 2020-08-31
KR102477105B1 (ko) 2022-12-13
CA3086759A1 (en) 2019-07-11
CL2020001796A1 (es) 2021-01-22
CN111757882A (zh) 2020-10-09

Similar Documents

Publication Publication Date Title
ECSP20042640A (es) Derivados de indol 1, 3, 4, 5-tetrahidro-2h-pirido [4,3-b] para el tratamiento, alivio o prevención de trastornos asociados con agregados de tau como la enfermedad de alzheimer
DOP2018000204A (es) Moduladores alostéricos de receptores de acetilcolina nicotínicos
CL2019001512A1 (es) Tratamiento de enfermedades neurológicas.
UY31748A (es) Nuevos compuestos para el tratamiento de trastornos del snc (sistema nervioso central)
CL2011000488A1 (es) Compuestos derivados de pirazolo-pirimidinas sustituidas; composicion y combinacion farmaceutica que los comprenden; y su uso como inhibidores de pde9 para el tratamiento, alivio y/o prevencion de deterioros cognitivos relacionados con la percepcion, alzheimer,trastornos del sueño, trastorno bipolar, diabetes mellitus.
MX2019002429A (es) Tratamiento de la demencia.
CL2014000246A1 (es) Compuestos derivados fenil-3-aza-biciclo[3.1.0]hex-3-il-metanonas, inhibidores del transportador de glicina (glyt1); composicion farmaceutica que los contiene; combinacion farmaceutica; y su uso en el tratamiento de alzheimer, alteraciones cognitivas en esquizofrenia, psicosis, trastornos psiquiatricos, entre otros
MX2019000980A (es) Compuestos y composiciones y usos de los mismos.
CL2019001891A1 (es) Derivados de bis-heteroarilo bicíclicos como moduladores de agregación de proteínas.
MX380252B (es) Crenezumab para usarse en el tratamiento de enfermedad de alzheimer.
CO2019002889A2 (es) Tratamientos de combinación que comprenden la administración de imidazopirazinonas
MX2020013115A (es) Compuestos de tetrahidrobenzofuro[2,3-c]piridina y beta-carbolina para el tratamiento, el alivio o la prevencion de trastornos asociados con los agregados de tau.
MX2020001855A (es) Composiciones farmacéuticas que contienen anticuerpos anti-beta-amiloides.
CL2015000559A1 (es) Compuestos derivados de 2-oxo-2,3-dihidro-indoles; su proceso de obtencion; composicion y combinacion farmaceutica que los comprende; y su uso para el tratamiento de trastornos del snc que son sintomas positivos o negativos de la esquizofrenia, el abuso de sustancias, la adiccion a alcohol y las drogas, enfermedad de alzheimer, enfermedad de parkinson, entre otras.
CO2019014090A2 (es) Agentes, usos y métodos para el tratamiento
UY37466A (es) N-hidroxiamidinheterociclos sustituidos como moduladores de la indolamina 2,3-dioxigenasa
CO2017003321A2 (es) Inhibidores de gingipaina de lisina
NI202000074A (es) Moduladores alostéricos de espiropiperidina de receptores nicotínicos de acetilcolina
MX380290B (es) Composiciones y métodos para el tratamiento y la prevención de trastornos neurodegenerativos.
CR20180368A (es) Compuestos de dihidroquinolinsulfonamida de alquilo
MX2019000982A (es) Compuestos y composiciones y usos de los mismos.
MX2016008968A (es) Compuestos organicos.
WO2017103892A3 (en) Composition for treating and preventing neurological diseases, neuroinflammation, and alzheimer's disease
MX377588B (es) Métodos de tratamiento de enfermedades y trastornos del neurodesarrollo.
EA202091395A1 (ru) ПРОИЗВОДНЫЕ 1,3,4,5-ТЕТРАГИДРО-2Н-ПИРИДО[4,3-b]ИНДОЛА ДЛЯ ЛЕЧЕНИЯ, ОБЛЕГЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ РАССТРОЙСТВ, СВЯЗАННЫХ С АГРЕГАТАМИ ТАУ, ТАКИХ КАК БОЛЕЗНЬ АЛЬЦГЕЙМЕРА